

JÃ,rgen Vestbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/648643/publications.pdf>

Version: 2024-02-01

489
papers

60,411
citations

1614

105
h-index

1139

230
g-index

502
all docs

502
docs citations

502
times ranked

32013
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of self-reported environmental mould exposure on COPD outcomes. <i>Pulmonology</i> , 2023, 29, 375-384.	2.1	4
2	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	5.6	72
3	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	6.7	34
4	Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. <i>Lancet Respiratory Medicine</i> , 2022, 10, 83-94.	10.7	19
5	Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population. <i>Respiratory Medicine</i> , 2022, 192, 106725.	2.9	8
6	Should e-cigarettes be licensed as medicines?. <i>BMJ</i> , 2022, 376, n2912.	6.0	2
7	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. <i>PLoS ONE</i> , 2022, 17, e0262898.	2.5	3
8	The environmental impact of inhaled therapy: making informed treatment choices. <i>European Respiratory Journal</i> , 2022, 60, 2102106.	6.7	14
9	Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. <i>European Respiratory Journal</i> , 2022, 59, 2102899.	6.7	6
10	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 25-33.	5.6	11
11	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	1.6	2
12	Prognosis of Patients with Chronic Obstructive Pulmonary Disease Not Eligible for Major Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 271-280.	5.6	8
13	Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study. <i>Respiratory Medicine</i> , 2022, 197, 106852.	2.9	2
14	Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 94-100.	4.0	1
15	Importance of Early COPD in Young Adults for Development of Clinical COPD. Findings from the Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1245-1256.	5.6	49
16	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 1690-1698.	4.0	10
17	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 689-698.	5.6	42
18	Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. <i>European Respiratory Journal</i> , 2021, 57, 2004055.	6.7	20

#	ARTICLE	IF	CITATIONS
19	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	6.7	43
20	Increased serum SP-D in identification of high-risk smokers at high risk of COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1005-L1010.	2.9	2
21	Safety data in randomised real-world evidence studies: Salford Lung Study learnings. <i>ERJ Open Research</i> , 2021, 7, 00966-2020.	2.6	1
22	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. <i>Frontiers in Immunology</i> , 2021, 12, 668113.	4.8	7
23	Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1963-1973.	5.3	12
24	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. <i>Respiratory Research</i> , 2021, 22, 155.	3.6	5
25	Transformations of practice in online exercise training for patients with COPD led by physiotherapists – a qualitative study. <i>Disability and Rehabilitation</i> , 2021, , 1-10.	1.8	0
26	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021, 7, 00902-2020.	2.6	15
27	The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea. <i>Sleep and Biological Rhythms</i> , 2021, 19, 399-408.	1.0	0
28	Corticosteroid Resistance in Smokers – A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2734.	2.4	0
29	Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 910-920.	5.6	47
30	Supernormal lung function and risk of COPD: A contemporary population-based cohort study. <i>EClinicalMedicine</i> , 2021, 37, 100974.	7.1	20
31	Management of chronic obstructive pulmonary disease. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0,784314 rgBT /Over 0,5 P	0.5	0
32	Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19. <i>European Respiratory Journal</i> , 2021, 58, 2101907.	6.7	9
33	Stigma: an unmet public health priority in COPD. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 955-956.	10.7	7
34	Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease. <i>Respiratory Medicine</i> , 2021, 186, 106529.	2.9	0
35	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339.	6.7	26
36	Impact of the UK lockdown on people at risk of COPD. <i>ERJ Open Research</i> , 2021, 7, 00358-2021.	2.6	0

#	ARTICLE	IF	CITATIONS
37	Another public health catastrophe. <i>Lancet, The</i> , 2021, 398, 2243.	13.7	2
38	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. <i>Biomedicines</i> , 2021, 9, 1837.	3.2	6
39	Real-World Data and Randomised Controlled Trials: The Salford Lung Study. <i>Advances in Therapy</i> , 2020, 37, 977-997.	2.9	9
40	Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study. <i>Journal of Sleep Research</i> , 2020, 29, e12979.	3.2	24
41	The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2170-2184.	5.7	219
42	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3214-3221.	5.8	9
43	Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 671-680.	5.6	70
44	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 463-474.	2.1	9
45	RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION. <i>Chest</i> , 2020, 158, A1755-A1760.	0.8	1
46	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. <i>Respiratory Research</i> , 2020, 21, 263.	3.6	1
47	Telemediated Training in the Home as a Part of the Everyday Life and Practice With Very Severe Chronic Obstructive Pulmonary Disease. <i>Qualitative Health Research</i> , 2020, 30, 2132-2145.	2.1	6
48	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020, 29, 200199.	7.1	73
49	Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. <i>Respiratory Research</i> , 2020, 21, 202.	3.6	13
50	Automatic oxygen titration with O2matic® to patients admitted with COVID-19 and hypoxemic respiratory failure. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1833695.	1.5	8
51	The global impact of <i>Aspergillus</i> infection on COPD. <i>BMC Pulmonary Medicine</i> , 2020, 20, 241.	2.0	52
52	Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD: a contemporary population-based cohort. <i>Thorax</i> , 2020, 75, 944-954.	5.6	17
53	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020, 10, 350.	2.4	11
54	Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. <i>ERJ Open Research</i> , 2020, 6, 00044-2020.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. <i>Respiratory Medicine</i> , 2020, 173, 106185.	2.9	3
56	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020, 158, 952-964.	0.8	62
57	Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1757274.	1.5	21
58	Outcomes consequent to "early" COPD for interventional studies. <i>European Respiratory Journal</i> , 2020, 55, 2000073.	6.7	2
59	&p>FEV₁ is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease&p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1135-1142.	2.3	35
60	World No Tobacco Day: smoking, nicotine and children. <i>European Respiratory Journal</i> , 2020, 55, 2001633.	6.7	5
61	World No Tobacco Day: what's in it for us?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L1008-L1009.	2.9	5
62	&p>Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk&p>. <i>International Journal of COPD</i> , 2020, Volume 15, 543-552.	2.3	15
63	Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. <i>Living Better, Longer, or Both?. American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1463-1464.	5.6	6
64	The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials Network (DECODE-NET): rationale and vision. <i>European Respiratory Journal</i> , 2020, 56, 2000627.	6.7	10
65	COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 635-637.	5.6	17
66	Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1307-1310.	5.6	8
67	A rational approach to e-cigarettes: challenging ERS policy on tobacco harm reduction. <i>European Respiratory Journal</i> , 2020, 55, 2000355.	6.7	5
68	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020, 55, 1902119.	6.7	26
69	Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000470.	3.0	35
70	Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020, 221, 1973-1977.	4.0	8
71	Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2020, 10, e035640.	1.9	9
72	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020, 75, 520-527.	5.6	97

#	ARTICLE	IF	CITATIONS
73	Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 210-218.	5.6	54
74	Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies. ERJ Open Research, 2020, 6, 00193-2019.	2.6	2
75	A new Cochrane review on electronic cigarettes for smoking cessation: should we change our practice?. European Respiratory Journal, 2020, 56, 2004083.	6.7	7
76	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. ERJ Open Research, 2020, 6, 00193-2020.	2.6	14
77	Editorial: Risk Prediction in Smokers. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 297-299.	0.7	0
78	Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. Respiratory Medicine, 2019, 155, 141-147.	2.9	25
79	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respiratory Medicine, the, 2019, 7, 699-709.	10.7	111
80	Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry. European Respiratory Journal, 2019, 54, 1900734.	6.7	48
81	β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. Thorax, 2019, 74, 934-940.	5.6	8
82	Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Research, 2019, 5, 00036-2018.	2.6	29
83	Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related Hospitalization and Mortality. JAMA - Journal of the American Medical Association, 2019, 321, 2412.	7.4	2
84	Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. ERJ Open Research, 2019, 5, 00072-2019.	2.6	20
85	<p>Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population</p>. International Journal of COPD, 2019, Volume 14, 853-861.	2.3	20
86	Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respiratory Research, 2019, 20, 63.	3.6	23
87	Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients. ERJ Open Research, 2019, 5, 00021-2019.	2.6	4
88	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1900217.	6.7	25
89	Association of Cardiovascular Disease With Respiratory Disease. Journal of the American College of Cardiology, 2019, 73, 2166-2177.	2.8	104
90	Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. Scientific Reports, 2019, 9, 4064.	3.3	18

#	ARTICLE	IF	CITATIONS
91	Was the implementation strategy of the ProACT trial adequately proactive?. <i>Breathe</i> , 2019, 15, 77-80.	1.3	3
92	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019, 5, 00203-2018.	2.6	4
93	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019, 53, 1900164.	6.7	1,223
94	Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019, 53, 1900278.	6.7	2
95	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019, 51, 494-505.	21.4	257
96	ERS and tobacco harm reduction. <i>European Respiratory Journal</i> , 2019, 54, 1902009.	6.7	42
97	End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2019, 160, 105814.	2.9	15
98	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	3.2	11
99	Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. <i>Respiratory Medicine</i> , 2019, 147, 58-65.	2.9	5
100	A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. <i>ERJ Open Research</i> , 2019, 5, 00136-2019.	2.6	15
101	The Pressing Need to Redefine "COPD". <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 380-383.	0.7	12
102	Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. <i>European Respiratory Journal</i> , 2018, 51, 1702681.	6.7	33
103	β2-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , 2018, 15, 608-614.	3.2	22
104	Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. <i>European Respiratory Journal</i> , 2018, 51, 1701531.	6.7	28
105	Left ventricular volume and wall stress are linked to lung function impairment in COPD. <i>International Journal of Cardiology</i> , 2018, 261, 172-178.	1.7	27
106	The emerging Chinese COPD epidemic. <i>Lancet, The</i> , 2018, 391, 1642-1643.	18.7	5
107	Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. <i>European Respiratory Journal</i> , 2018, 51, 1800120.	6.7	25
108	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 51-57.	5.6	192

#	ARTICLE	IF	CITATIONS
109	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018, 73, 431-438.	5.6	57
110	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1540-1551.	5.6	185
111	Long-Acting \hat{I}^2 -Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1641-1644.	5.6	4
112	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 1076-1084.	13.7	433
113	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018, 51, 1702146.	6.7	60
114	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2018, 51, 1701393.	6.7	27
115	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2037-2047.e10.	2.9	138
116	The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018, 134, 79-85.	2.9	45
117	Automated oxygen control with O2matic [®] during admission with exacerbation of COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3997-4003.	2.3	19
118	Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis. <i>Frontiers in Immunology</i> , 2018, 9, 3013.	4.8	17
119	The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. <i>International Journal of COPD</i> , 2018, Volume 13, 3885-3894.	2.3	2
120	What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs. <i>International Journal of COPD</i> , 2018, Volume 13, 3485-3492.	2.3	21
121	Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply. <i>Lancet</i> , The, 2018, 392, 1113-1114.	13.7	2
122	Validation of lung density indices by cardiac CT for quantification of lung emphysema. <i>International Journal of COPD</i> , 2018, Volume 13, 3321-3330.	2.3	2
123	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018, 52, 1801219.	6.7	166
124	Exhaled breath condensate in chronic obstructive pulmonary disease: methodological challenges and clinical application. <i>Minerva Respiratory Medicine</i> , 2018, 57, .	0.2	3
125	Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , 2018, 52, 1801230.	6.7	51
126	Childhood Asthma, Lung Function Trajectories, and Chronic Obstructive Pulmonary Disease: An Additional Step Forward. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1030-1031.	3.2	0

#	ARTICLE	IF	CITATIONS
127	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. <i>Human Molecular Genetics</i> , 2018, 27, 3801-3812.	2.9	32
128	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018, Volume 13, 1125-1134.	2.3	14
129	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1126-1137.	2.8	48
130	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018, 39, 3128-3134.	2.2	30
131	Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. <i>Respiratory Medicine</i> , 2018, 141, 198-206.	2.9	14
132	Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , 2018, 52, 1800296.	6.7	15
133	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 47-55.	5.6	46
134	Iron Deficiency in COPD Associates with Increased Pulmonary Artery Pressure Estimated by Echocardiography. <i>Heart Lung and Circulation</i> , 2017, 26, 101-104.	0.4	23
135	Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2017, 26, 160073.	7.1	93
136	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. <i>Respirology</i> , 2017, 22, 575-601.	2.3	299
137	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017, 49, 1700214.	6.7	536
138	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 557-582.	5.6	2,393
139	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017, 53, 128-149.	0.8	173
140	Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. <i>Clinical Chemistry</i> , 2017, 63, 823-832.	3.2	45
141	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. <i>Nature Genetics</i> , 2017, 49, 426-432.	21.4	306
142	Paper acceptance time in respiratory research: room for improvement?. <i>European Respiratory Journal</i> , 2017, 49, 1601951.	6.7	1
143	Small airway dysfunction in well-treated never-smoking HIV-infected individuals. <i>European Respiratory Journal</i> , 2017, 49, 1602186.	6.7	12
144	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 35-46.	2.9	55

#	ARTICLE	IF	CITATIONS
145	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017, 103, 1536-1542.	2.9	41
146	Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1082-1083.	5.6	6
147	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 1919-1929.	13.7	326
148	Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 426-434.	10.7	106
149	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. <i>Archivos De Bronconeumología</i> , 2017, 53, 128-149.	0.8	312
150	HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1819.	2.8	0
151	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	6.7	438
152	Susceptibility to exacerbation in COPD. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, e29.	10.7	21
153	Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017, 31, 1973-1977.	2.2	6
154	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	6.7	131
155	Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 2247-2255.	13.7	88
156	The prognostic significance of lung function in stable heart failure outpatients. <i>Clinical Cardiology</i> , 2017, 40, 1145-1151.	1.8	18
157	Taken to task: what is and is not an appropriate response to an ERS guidelines task force?. <i>European Respiratory Journal</i> , 2017, 50, 1700952.	6.7	1
158	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 955-959.e6.	2.5	35
159	Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 25.	2.6	12
160	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017, 131, 27-34.	2.9	29
161	The era of research collaborations: new models for working together. <i>European Respiratory Journal</i> , 2017, 49, 1601848.	6.7	11
162	Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1096.e1-1096.e17.	2.5	48

#	ARTICLE	IF	CITATIONS
163	Exposure Interaction: A Lifelong Phenomenon with Relevance to Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 947-948.	5.6	0
164	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. <i>European Respiratory Journal</i> , 2017, 50, 1700671.	6.7	69
165	The TRINITY study: Twitter discussion from a respiratory journal club – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2017, 5, e26.	10.7	0
166	Prevalence of airflow obstruction in patients with stable systolic heart failure. <i>BMC Pulmonary Medicine</i> , 2017, 17, 6.	2.0	20
167	Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. <i>Lancet Respiratory Medicine</i> , 2017, 5, 466-468.	10.7	5
168	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 881-888.	5.6	49
169	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	2.9	236
170	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 17-22.	5.6	42
171	Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. <i>Clinical Epidemiology</i> , 2017, Volume 9, 231-243.	3.0	16
172	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017, Volume 12, 2917-2928.	2.3	31
173	A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations – The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol. <i>BMC Pulmonary Medicine</i> , 2017, 17, 114.	2.0	10
174	Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 164.	2.0	18
175	COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , 2017, 18, 90.	3.6	19
176	Fletcher and Peto 40 Years On. A Tribute and Reflection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1420-1422.	5.6	7
177	Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016, 48, 880-888.	6.7	60
178	Effectiveness of Fluticasone Furoate–Vilanterol in COPD. <i>New England Journal of Medicine</i> , 2016, 375, 2605-2607.	27.0	4
179	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016, 16, 713.	2.9	61
180	Overview of Safety of Fluticasone Furoate, Vilanterol, or Their Combination in COPD Patients With Moderate Airflow Obstruction: The Summit Trial. <i>Chest</i> , 2016, 150, 922A.	0.8	0

#	ARTICLE	IF	CITATIONS
181	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016, 114, 27-37.	2.9	113
182	Personality Traits and Mental Symptoms are Associated with Impact of Chronic Obstructive Pulmonary Disease on Patients' Daily Life. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 773-778.	1.6	6
183	Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 454-462.	10.7	119
184	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet</i> , 2016, 387, 1817-1826.	13.7	378
185	Indacaterol versus Glycopyrronium versus Salmeterol versus Fluticasone for COPD. <i>New England Journal of Medicine</i> , 2016, 374, 2222-2234.	27.0	688
186	Natural experiments and large databases in respiratory and cardiovascular disease. <i>European Respiratory Review</i> , 2016, 25, 130-134.	7.1	3
187	Effectiveness of Fluticasone Furoate versus Vilanterol for COPD in Clinical Practice. <i>New England Journal of Medicine</i> , 2016, 375, 1253-1260.	27.0	172
188	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016, 119, 87-95.	2.9	29
189	Natural history of COPD: Focusing on change in FEV ₁ . <i>Respirology</i> , 2016, 21, 34-43.	2.3	40
190	Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis. <i>Hemodialysis International</i> , 2016, 20, 68-77.	0.9	20
191	The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , 2016, 194, 889-895.	3.3	25
192	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet</i> , 2016, 388, 963-973.	13.7	351
193	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016, 6, 114.	4.6	14
194	High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. <i>Respiratory Research</i> , 2016, 17, 125.	3.6	57
195	A systematic review of breath analysis and detection of volatile organic compounds in COPD. <i>Journal of Breath Research</i> , 2016, 10, 034002.	3.0	37
196	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 980-989.	10.7	38
197	Long-term Course of Depression Trajectories in Patients With COPD. <i>Chest</i> , 2016, 149, 916-926.	0.8	61
198	Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 48-57.	5.6	52

#	ARTICLE	IF	CITATIONS
199	Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 965-974.	5.6	331
200	A comparison of COPD patients with and without ACOS in the ECLIPSE study. European Respiratory Journal, 2016, 47, 1559-1562.	6.7	35
201	Chronic Mucus Hypersecretion and the Natural History of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 602-603.	5.6	6
202	Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. European Respiratory Journal, 2016, 47, 1365-1373.	6.7	64
203	Absence of Pneumocystis jirovecii Colonization in Human Immunodeficiency Virus-Infected Individuals With and Without Airway Obstruction and With Undetectable Viral Load. Open Forum Infectious Diseases, 2016, 3, ofw044.	0.9	5
204	Decade of the lung – a call for action to promote lung health globally. Lancet Respiratory Medicine, the, 2016, 4, e3-e4.	10.7	3
205	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
206	The European Respiratory Society evaluates its 2013 – 2018 strategic plan implementation. European Respiratory Journal, 2016, 47, 693-698.	6.7	3
207	COPD. , 2016, , 751-766.e7.		2
208	Psychometric Properties of the COPD-Specific Beliefs About Medicine Questionnaire in an Outpatient Population: A Rasch-Analysis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 748-757.	0.7	4
209	Chronic obstructive pulmonary disease. Nature Reviews Disease Primers, 2015, 1, 15076.	30.5	444
210	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulmonary Medicine, 2015, 15, 160.	2.0	43
211	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. Respiratory Research, 2015, 16, 101.	3.6	41
212	Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 293.	2.3	22
213	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 523-525.	5.6	338
214	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	7.1	72
215	Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. Respiratory Medicine, 2015, 109, 1562-1568.	2.9	24
216	Changes in GOLD: today and tomorrow. Lancet Respiratory Medicine, the, 2015, 3, 424-426.	10.7	4

#	ARTICLE	IF	CITATIONS
217	Gastroesophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. <i>Respirology</i> , 2015, 20, 101-107.	2.3	61
218	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312.	3.2	126
219	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015, 12, 27-34.	3.2	131
220	Low Use and Adherence to Maintenance Medication in Chronic Obstructive Pulmonary Disease in the General Population. <i>Journal of General Internal Medicine</i> , 2015, 30, 51-59.	2.6	54
221	Overweight and Obesity May Lead to Under-diagnosis of Airflow Limitation: Findings from the Copenhagen City Heart Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 5-13.	1.6	38
222	The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , 2015, 70, 757-763.	5.6	11
223	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015, 373, 111-122.	27.0	974
224	Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 8.	3.0	28
225	Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. <i>Chest</i> , 2015, 148, 16-23.	0.8	22
226	Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L1114-L1124.	2.9	34
227	One-year change in health status and subsequent outcomes in COPD. <i>Thorax</i> , 2015, 70, 420-425.	5.6	50
228	Hospitalized Exacerbations of COPD. <i>Chest</i> , 2015, 147, 999-1007.	0.8	269
229	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	5.6	166
230	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	6.7	138
231	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015, 46, 1308-1321.	6.7	434
232	Prevention of COPD exacerbations: medications and other controversies. <i>ERJ Open Research</i> , 2015, 1, 00011-2015.	2.6	15
233	Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. <i>Thorax</i> , 2015, 70, 862-872.	5.6	37
234	Fibrinogen and α_1 -antitrypsin in COPD exacerbations. <i>Thorax</i> , 2015, 70, 1014-1021.	5.6	16

#	ARTICLE	IF	CITATIONS
235	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015, 109, 1147-1154.	2.9	40
236	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2015, 109, 1138-1146.	2.9	77
237	Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. <i>Thorax</i> , 2015, 70, 33-40.	5.6	80
238	Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015, 2, 204-213.	0.7	9
239	Prognostic Value of C-Reactive Protein, Leukocytes, and Vitamin D in Severe Chronic Obstructive Pulmonary Disease. <i>Scientific World Journal, The</i> , 2014, 2014, 1-7.	2.1	20
240	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 23-34.	0.7	76
241	Validation of the i-BODE Index as a Predictor of hospitalization and Mortality in Patients with COPD Participating in Pulmonary Rehabilitation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 381-387.	1.6	25
242	Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L887-L895.	2.9	31
243	Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 678-687.	2.9	19
244	COPD assessment: I, II, III, IV and/or A, B, C, D. <i>European Respiratory Journal</i> , 2014, 43, 949-950.	6.7	8
245	Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. <i>Respiratory Research</i> , 2014, 15, 147.	3.6	46
246	Socioeconomic Status and Prognosis of COPD in Denmark. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 431-437.	1.6	40
247	S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. <i>Thorax</i> , 2014, 69, A28-A29.	5.6	1
248	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014, 69, 718-723.	5.6	151
249	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014, 108, 1647-1654.	2.9	22
250	Chronic Obstructive Pulmonary Disease: Different Risk Factors and Different Natural Histories?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 968-970.	5.6	5
251	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , 2014, 83, 2093-2101.	2.6	30
252	Prevalence of night-time dyspnoea in COPD and its implications for prognosis. <i>European Respiratory Journal</i> , 2014, 43, 1590-1598.	6.7	45

#	ARTICLE	IF	CITATIONS
253	Changes in physical activity and all-cause mortality in COPD. <i>European Respiratory Journal</i> , 2014, 44, 1199-1209.	6.7	137
254	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. <i>Respiratory Research</i> , 2014, 15, 103.	3.6	53
255	Association Between Vitamin D Status and COPD Phenotypes. <i>Lung</i> , 2014, 192, 493-497.	3.3	11
256	COPD. <i>Clinics in Chest Medicine</i> , 2014, 35, 1-6.	2.1	111
257	Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. <i>BMC Pulmonary Medicine</i> , 2014, 14, 43.	2.0	36
258	Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. <i>Respiratory Medicine</i> , 2014, 108, 729-736.	2.9	83
259	Microfibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014, 108, 1336-1344.	2.9	44
260	COPD drugs: the urgent need for innovation. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 14-15.	10.7	5
261	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	6.7	154
262	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014, 69, 666-672.	5.6	125
263	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	5.6	130
264	Persistence of Depressive Symptoms in Patients With COPD: A 3-Year Longitudinal Follow-up Analysis of the ECLIPSE Study Cohort. <i>Chest</i> , 2014, 146, 33A.	0.8	0
265	Are patients with COPD treated with NIV in accordance with national guidelines? An internal audit. <i>European Clinical Respiratory Journal</i> , 2014, 1, 24506.	1.5	0
266	Chronic bronchitis: so much more than just a smoker's cough. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 760-760.	1.2	2
267	A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study. <i>Chest</i> , 2014, 145, 408A.	0.8	4
268	Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. <i>PLoS ONE</i> , 2014, 9, e91621.	2.5	25
269	Reorganisation of acute referral to an emergency department resulted in fewer admissions for chronic obstructive pulmonary disease but in higher rates of non-invasive ventilation. <i>Danish Medical Journal</i> , 2014, 61, A4958.	0.5	1
270	Reply: Correctly Defining Criteria for Diagnosing Chronic Obstructive Pulmonary Disease Matters. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 230-231.	5.6	7

#	ARTICLE	IF	CITATIONS
271	Inflammatory Biomarkers and Exacerbations in Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2353.	7.4	326
272	Impact of diagnostic criteria on the prevalence of <scp>COPD</scp>. Clinical Respiratory Journal, 2013, 7, 297-303.	1.6	17
273	Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respiratory Medicine, 2013, 107, 1578-1588.	2.9	42
274	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384.	2.9	328
275	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal, 2013, 41, 1017-1022.	6.7	81
276	Factors associated with change in exacerbation frequency in COPD. Respiratory Research, 2013, 14, 79.	3.6	58
277	The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377.	1.6	67
278	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	5.6	7,792
279	Resting heart rate is a predictor of mortality in COPD. European Respiratory Journal, 2013, 42, 341-349.	6.7	100
280	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. Human Genetics, 2013, 132, 79-90.	3.8	45
281	Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respiratory Medicine, the, 2013, 1, 543-550.	10.7	102
282	Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respiratory Medicine, 2013, 107, 1722-1730.	2.9	25
283	NICE and GOLD response. Lancet Respiratory Medicine, the, 2013, 1, 442.	10.7	1
284	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respiratory Medicine, the, 2013, 1, 210-223.	10.7	301
285	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine, the, 2013, 1, 129-136.	10.7	224
286	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	5.6	257
287	FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. European Respiratory Journal, 2013, 42, 1391-1401.	6.7	87
288	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. Annals of Nutrition and Metabolism, 2013, 63, 239-247.	1.9	46

#	ARTICLE	IF	CITATIONS
289	Predictors of Objective Cough Frequency in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 943-949.	5.6	77
290	What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1036-1037.	5.6	19
291	Reply: Comorbidities and Chronic Obstructive Pulmonary Disease: Is There a Place for Lung Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1368-1368.	5.6	0
292	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. European Respiratory Journal, 2013, 41, 12-17.	6.7	27
293	Letter to the editors. Thorax, 2013, 68, 387.1-388.	5.6	2
294	High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. European Journal of Preventive Cardiology, 2013, 20, 1005-1012.	1.8	47
295	Short telomere length, lung function and chronic obstructive pulmonary disease in 46â€¦396 individuals. Thorax, 2013, 68, 429-435.	5.6	134
296	Hospitalised for Chronic Obstructive Pulmonary Disease: On a Dangerous Route. Respiration, 2013, 85, 11-12.	2.6	1
297	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646.	6.7	164
298	Characteristics of Undertreatment in COPD in the General Population. Chest, 2013, 144, 1811-1818.	0.8	34
299	Enzyme-Linked Immunosorbent Assay Characterization of Basal Variation and Heritability of Systemic Microfibrillar-Associated Protein 4. PLoS ONE, 2013, 8, e82383.	2.5	20
300	Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure. International Journal of COPD, 2013, 8, 215.	2.3	33
301	Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues: Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular Conditions. PLoS ONE, 2013, 8, e82243.	2.5	70
302	Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation. Current Drug Targets, 2013, 14, 235-245.	2.1	22
303	Authors'™ reply. International Journal of COPD, 2013, 8, 381.	2.3	0
304	The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. Journal of Human Hypertension, 2012, 26, 476-484.	2.2	44
305	Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal, 2012, 39, 38-45.	6.7	180
306	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1238-1247.	5.6	117

#	ARTICLE	IF	CITATIONS
307	The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what?. <i>Clinical Respiratory Journal</i> , 2012, 6, 208-214.	1.6	143
308	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012, 67, 701-708.	5.6	160
309	Can patients with COPD self-manage?. <i>Lancet</i> , The, 2012, 380, 624-625.	13.7	15
310	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 291-297.	2.5	193
311	Are pharmacists reducing COPD's impact through smoking cessation and assessing inhaled steroid use?. <i>Respiratory Medicine</i> , 2012, 106, 230-234.	2.9	9
312	Is chronic obstructive pulmonary disease associated with increased arterial stiffness?. <i>Respiratory Medicine</i> , 2012, 106, 397-405.	2.9	15
313	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	5.6	353
314	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. <i>Human Molecular Genetics</i> , 2012, 21, 947-957.	2.9	216
315	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 100.	2.4	41
316	Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 975-981.	5.6	355
317	Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 982-988.	5.6	198
318	GOLD and the fixed ratio. <i>International Journal of COPD</i> , 2012, 7, 663.	2.3	0
319	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. <i>PLoS ONE</i> , 2012, 7, e37483.	2.5	633
320	Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. <i>Danish Medical Journal</i> , 2012, 59, A4396.	0.5	16
321	Recommendations for epidemiological studies on COPD. <i>European Respiratory Journal</i> , 2011, 38, 1261-1277.	6.7	105
322	Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 507-513.	5.6	98
323	Prevalence of COPD in Copenhagen. <i>Respiratory Medicine</i> , 2011, 105, 410-417.	2.9	51
324	Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. <i>Respiratory Medicine</i> , 2011, 105, 1338-1344.	2.9	21

#	ARTICLE	IF	CITATIONS
325	Cardiovascular Morbidity in COPD: A Study of the General Population. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 7, 5-10.	1.6	51
326	Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. Liver International, 2011, 31, 1381-1387.	3.9	7
327	Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal, 2011, 5, 44-49.	1.6	78
328	Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respiratory Research, 2011, 12, 3.	3.6	88
329	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research, 2011, 12, 71.	3.6	60
330	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 604-611.	5.6	250
331	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322.	5.6	157
332	To Use or Not to Use. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 284-285.	5.6	3
333	The EXACT-Pro: Measuring Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 287-288.	5.6	15
334	Tiotropium for Treatment of Stable COPD: A Meta-analysis of Clinically Relevant Outcomes. Respiratory Care, 2011, 56, 477-487.	1.6	53
335	Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza. New England Journal of Medicine, 2011, 365, 2541-2542.	27.0	119
336	Candidate genes for COPD in two large data sets. European Respiratory Journal, 2011, 37, 255-263.	6.7	44
337	GOLD and the fixed ratio. European Respiratory Journal, 2011, 38, 481-482.	6.7	7
338	C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax, 2011, 66, 197-204.	5.6	70
339	Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax, 2011, 66, 903-909.	5.6	26
340	Republished editorial: Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. Postgraduate Medical Journal, 2011, 87, 793-794.	1.8	0
341	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal, 2011, 37, 508-515.	6.7	152
342	Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. Thorax, 2011, 66, 643-645.	5.6	4

#	ARTICLE	IF	CITATIONS
343	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. <i>New England Journal of Medicine</i> , 2011, 365, 1184-1192.	27.0	811
344	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 121-135.	1.6	43
345	Clinical Assessment of COPD. , 2011, , 21-31.		1
346	Î±1 -Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large Cohorts. <i>Chest</i> , 2010, 138, 1125-1132.	0.8	77
347	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010, 11, 122.	3.6	952
348	Management and survival of patients admitted with an exacerbation of COPD: Comparison of two Danish patient cohorts. <i>Clinical Respiratory Journal</i> , 2010, 4, 208-214.	1.6	26
349	Choice of medications when treating stable COPD. <i>Clinical Respiratory Journal</i> , 2010, 4, 195-196.	1.6	0
350	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010, 35, 532-539.	6.7	59
351	Aortic Augmentation Index: Reference Values in a Large Unselected Population by Means of the SphygmoCor Device. <i>American Journal of Hypertension</i> , 2010, 23, 180-185.	2.0	95
352	Onset of Effect of Acclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 331-336.	1.6	28
353	Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Neededâ€”Urgently. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 863-864.	5.6	85
354	Multistudy Fine Mapping of Chromosome 2q Identifies <i>XRCC5</i> as a Chronic Obstructive Pulmonary Disease Susceptibility Gene. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 605-613.	5.6	29
355	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1128-1138.	27.0	2,359
356	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010, 104, 849-857.	2.9	171
357	Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. <i>Respiratory Medicine</i> , 2010, 104, 1297-1303.	2.9	49
358	Genetic influences on chronic obstructive pulmonary disease â€” A twin study. <i>Respiratory Medicine</i> , 2010, 104, 1890-1895.	2.9	69
359	Chronic Obstructive Pulmonary Disease Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 598-604.	5.6	898
360	Cardiovascular events in patients with COPD: TORCH Study results. <i>Thorax</i> , 2010, 65, 719-725.	5.6	177

#	ARTICLE	IF	CITATIONS
361	The prognostic importance of lung function in patients admitted with heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 685-691.	7.1	97
362	The repeatability of interleukin-6, tumor necrosis factor- α , and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , 2009, 4, 149.	2.3	42
363	Lung function decline in COPD trials. <i>European Respiratory Journal</i> , 2009, 33, 708-709.	6.7	4
364	Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. <i>European Respiratory Journal</i> , 2009, 34, 641-647.	6.7	387
365	Prevalence and Progression of Osteoporosis in Patients With COPD. <i>Chest</i> , 2009, 136, 1456-1465.	0.8	240
366	Increased T-regulatory cells within lymphocyte follicles in moderate COPD. <i>European Respiratory Journal</i> , 2009, 34, 89-94.	6.7	63
367	Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. <i>Thorax</i> , 2009, 64, 950-955.	5.6	40
368	Methods for therapeutic trials in COPD: lessons from the TORCH trial. <i>European Respiratory Journal</i> , 2009, 34, 1018-1023.	6.7	24
369	Adherence to inhaled therapy, mortality and hospital admission in COPD. <i>Thorax</i> , 2009, 64, 939-943.	5.6	404
370	A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. <i>European Respiratory Journal</i> , 2009, 33, 1039-1044.	6.7	69
371	Biomarkers in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 543-545.	3.5	62
372	Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1165-1166.	1.9	7
373	Impulse oscillometry in COPD: Identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , 2009, 103, 136-143.	2.9	93
374	Improved survival prediction from lung function data in a large population sample. <i>Respiratory Medicine</i> , 2009, 103, 442-448.	2.9	44
375	Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , 2009, 103, 1572-1579.	2.9	74
376	COPD phenotype description using principal components analysis. <i>Respiratory Research</i> , 2009, 10, 41.	3.6	53
377	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009, 10, 59.	3.6	287
378	Sex Differences in Emphysema and Airway Disease in Smokers. <i>Chest</i> , 2009, 136, 1480-1488.	0.8	88

#	ARTICLE	IF	CITATIONS
379	Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. <i>European Journal of Human Genetics</i> , 2008, 16, 1083-1090.	2.8	35
380	Evidence for an asthma risk locus on chromosome Xp: a replication linkage study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1235-1238.	5.7	8
381	CD8 chemokine receptors in chronic obstructive pulmonary disease. <i>Clinical and Experimental Immunology</i> , 2008, 154, 56-63.	2.6	19
382	Chronic obstructive pulmonary disease in patients admitted with heart failure. <i>Journal of Internal Medicine</i> , 2008, 264, 361-369.	6.0	106
383	Statistical analysis of COPD exacerbations. <i>European Respiratory Journal</i> , 2008, 32, 1421-1422.	6.7	4
384	Natural Histories of Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 878-883.	3.5	59
385	Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). <i>European Respiratory Journal</i> , 2008, 31, 869-873.	6.7	591
386	Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 500-505.	5.6	268
387	Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation. <i>Human Molecular Genetics</i> , 2008, 17, 1890-1903.	2.9	58
388	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 332-338.	5.6	692
389	Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. <i>Thorax</i> , 2008, 63, 1064-1069.	5.6	133
390	COPD, diagrams and traditions: time to move on?. <i>Thorax</i> , 2008, 63, 755-756.	5.6	2
391	Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. <i>European Respiratory Journal</i> , 2008, 32, 17-24.	6.7	87
392	COPD-related morbidity and mortality after smoking cessation: status of the evidence. <i>European Respiratory Journal</i> , 2008, 32, 844-853.	6.7	224
393	MUC5B Is the Major Mucin in the Gel Phase of Sputum in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1033-1039.	5.6	120
394	COPD Stage and Risk of Hospitalization for Infectious Disease*. <i>Chest</i> , 2008, 134, 46-53.	0.8	55
395	The Many "Small COPDs". <i>Chest</i> , 2008, 134, 623-627.	0.8	102
396	A functional CD86 polymorphism associated with asthma and related allergic disorders. <i>Journal of Medical Genetics</i> , 2007, 44, 509-515.	3.2	23

#	ARTICLE	IF	CITATIONS
397	COPD: Who Has it, Who Hasn't " and Then What ?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2007, 4, 303-304.	1.6	13
398	Systemic inflammation and progression of COPD. Thorax, 2007, 62, 469-470.	5.6	10
399	Chronic Cough and Phlegm in Young Adults. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 2-3.	5.6	11
400	C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 250-255.	5.6	456
401	Use of different exhaled nitric oxide multiple flow rate models in COPD. European Respiratory Journal, 2007, 29, 651-659.	6.7	48
402	A Pooled Analysis of FEV 1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo. Chest, 2007, 131, 682-689.	0.8	121
403	Exhaled CO, a predictor of lung function?. Respiratory Medicine, 2007, 101, 581-586.	2.9	10
404	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	27.0	2,963
405	CD4-Regulatory Cells in COPD Patients. Chest, 2007, 132, 156-163.	0.8	105
406	Association of PTGDR gene polymorphisms with asthma in two Caucasian populations. Genes and Immunity, 2007, 8, 398-403.	4.1	25
407	Quantitative linkage genome scan for atopy in a large collection of Caucasian families. Human Genetics, 2007, 121, 83-92.	3.8	14
408	COPD: the dangerous underestimate of 15%. Lancet, The, 2006, 367, 1216-1219.	13.7	220
409	Improving the care of COPD patients " suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 139-142.	2.3	11
410	Smoking reduction and biomarkers in two longitudinal studies. Addiction, 2006, 101, 1516-1522.	3.3	28
411	Family based association analysis of the IL2 and IL15 genes in allergic disorders. European Journal of Human Genetics, 2006, 14, 227-235.	2.8	39
412	Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 464a-465.	5.6	10
413	Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations. Proceedings of the American Thoracic Society, 2006, 3, 252-256.	3.5	26
414	Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 79-83.	5.6	487

#	ARTICLE	IF	CITATIONS
415	The natural history of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2006, 27, 627-643.	6.7	212
416	Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene. <i>Thorax</i> , 2006, 61, 874-879.	5.6	21
417	Developing COPD: a 25 year follow up study of the general population. <i>Thorax</i> , 2006, 61, 935-939.	5.6	480
418	Potential misclassification of causes of death from COPD. <i>European Respiratory Journal</i> , 2006, 28, 781-785.	6.7	131
419	Inhaled corticosteroids and decline of lung function in community residents with asthma. <i>Thorax</i> , 2006, 61, 100-104.	5.6	103
420	Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample: Findings from the Copenhagen City Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 79-83.	5.6	292
421	The severity of airways obstruction as a determinant of treatment response in COPD. <i>International Journal of COPD</i> , 2006, 1, 209-218.	2.3	16
422	COPD: A prevalence estimation model. <i>Respirology</i> , 2005, 10, 594-602.	2.3	11
423	Measuring bronchodilation in COPD clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 379-384.	2.4	100
424	Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. <i>Journal of Medical Genetics</i> , 2005, 43, e10-e10.	3.2	23
425	Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?. <i>European Respiratory Journal</i> , 2005, 26, 6-7.	6.7	16
426	Convergence of the epidemiology and pathology of COPD. <i>Thorax</i> , 2005, 61, 86-88.	5.6	72
427	Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005, 60, 301-304.	5.6	53
428	Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 460-464.	5.6	74
429	Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. <i>Thorax</i> , 2005, 60, 343-349.	5.6	20
430	Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005, 60, 992-997.	5.6	253
431	Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2005, 25, 269-274.	6.7	81
432	Acceptance of the smoking cessation intervention in a large population-based study: The Inter99 study. <i>Scandinavian Journal of Public Health</i> , 2005, 33, 138-145.	2.3	36

#	ARTICLE	IF	CITATIONS
433	Factor V Leiden Homozygosity, Dyspnea, and Reduced Pulmonary Function. Archives of Internal Medicine, 2005, 165, 2032.	3.8	19
434	Smoking reduction intervention in a large population-based study. The Inter99 study. Preventive Medicine, 2005, 40, 112-118.	3.4	27
435	Smoking cessation intervention in a large randomised population-based study. The Inter99 study.. Preventive Medicine, 2005, 40, 285-292.	3.4	62
436	It is possible to help smokers in early motivational stages to quit. The Inter99 study. Preventive Medicine, 2005, 40, 278-284.	3.4	58
437	COPD in the ECRHS. Thorax, 2004, 59, 89-90.	5.6	6
438	A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine and Tobacco Research, 2004, 6, 55-61.	2.6	103
439	Possible gene dosage effect of glutathione-S-transferases on atopic asthma: Using real-time PCR for quantification of GSTM1 and GSTT1 gene copy numbers. Human Mutation, 2004, 24, 208-214.	2.5	94
440	Validation of a Chronic Obstructive Pulmonary Disease screening questionnaire for population surveys. Respiratory Medicine, 2004, 98, 78-83.	2.9	39
441	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine, 2004, 98, 1045-1050.	2.9	73
442	Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. Respiratory Medicine, 2004, 98, 1207-1213.	2.9	133
443	Outpatient management of chronic obstructive pulmonary disease. Clinical Medicine, 2004, 4, 220-224.	1.9	0
444	Changes in Alcohol Intake and Mortality. Epidemiology, 2004, 15, 222-228.	2.7	78
445	A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics and Genomics, 2004, 14, 627-633.	5.7	51
446	Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 2003, 361, 449-456.	13.7	1,120
447	Inhaled Corticosteroids With/Without Long-Acting β_2 -Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients. Treatments in Respiratory Medicine, 2003, 2, 67-74.	1.2	93
448	Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. Journal of Epidemiology and Community Health, 2003, 57, 412-416.	3.7	84
449	Social position and mortality from respiratory diseases in males and females. European Respiratory Journal, 2003, 21, 821-826.	6.7	75
450	Chronic bronchitis in an elderly population. Age and Ageing, 2003, 32, 636-642.	1.6	44

#	ARTICLE	IF	CITATIONS
451	Inhaled glucocorticoids in COPD: immortal time bias. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 127.	5.6	4
452	Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. European Respiratory Journal, 2002, 20, 819-825.	6.7	266
453	Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. European Respiratory Journal, 2002, 20, 539-544.	6.7	224
454	Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax, 2002, 57, 967-972.	5.6	164
455	Smoking Reduction, Smoking Cessation, and Mortality: A 16-year Follow-up of 19,732 Men and Women from the Copenhagen Centre for Prospective Population Studies. American Journal of Epidemiology, 2002, 156, 994-1001.	3.4	165
456	Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. European Respiratory Journal, 2002, 20, 799-805.	6.7	487
457	Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 329-332.	5.6	249
458	Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in α_1 -Antitrypsin <i>MZ</i> Heterozygotes: A Longitudinal Study of the General Population. Annals of Internal Medicine, 2002, 136, 270.	3.9	145
459	Predictors of Smoking Reduction and Cessation in a Cohort of Danish Moderate and Heavy Smokers. Preventive Medicine, 2001, 33, 46-52.	3.4	73
460	Molecular Diagnosis of Intermediate and Severe α_1 -Antitrypsin Deficiency: <i>MZ</i> Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function Than <i>MM</i> Individuals. Clinical Chemistry, 2001, 47, 56-62.	3.2	45
461	Changes in smoking habits and risk of asthma: a longitudinal population based study. European Respiratory Journal, 2001, 18, 549-554.	6.7	50
462	Epidemiology of chronic obstructive pulmonary disease. European Respiratory Journal, 2001, 17, 982-994.	6.7	315
463	Peak Flow as Predictor of Overall Mortality in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 690-693.	5.6	60
464	Elevated Plasma Fibrinogen Associated with Reduced Pulmonary Function and Increased Risk of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1008-1011.	5.6	208
465	Another Piece of the Inhaled Corticosteroids-in-COPD Puzzle. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 514-515.	5.6	11
466	Increase in prevalence and severity of asthma in young adults in Copenhagen. Thorax, 2000, 55, 833-836.	5.6	48
467	Prognostic Value of Nutritional Status in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1856-1861.	5.6	867
468	Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 1999, 353, 1819-1823.	13.7	756

#	ARTICLE	IF	CITATIONS
469	Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. <i>European Respiratory Journal</i> , 1999, 13, 1109.	6.7	184
470	A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country. <i>Copenhagen Center for Prospective Population Studies. European Journal of Epidemiology</i> , 1998, 14, 579-585.	5.7	30
471	Mortality in women and men in relation to smoking. <i>International Journal of Epidemiology</i> , 1998, 27, 27-32.	1.9	132
472	A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma. <i>New England Journal of Medicine</i> , 1998, 339, 1194-1200.	27.0	1,120
473	Has risk associated with smoking increased? Results from the Copenhagen Center for Prospective Population Studies. <i>International Journal of Epidemiology</i> , 1997, 26, 1214-1218.	1.9	7
474	Alveolar Damage in AIDS-Related <i>Pneumocystis carinii</i> Pneumonia. <i>Chest</i> , 1997, 111, 1193-1199.	0.8	41
475	Rapid Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid and Serum Samples by Polymerase Chain Reaction: Correlation of Virus Isolation and Clinical Outcome for Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1997, 24, 878-883.	5.8	7
476	Is Diastolic Hypertension an Independent Risk Factor for Stroke in the Presence of Normal Systolic Blood Pressure in the Middle-aged and Elderly?. <i>American Journal of Hypertension</i> , 1997, 10, 634-639.	2.0	77
477	Prognostic Value of Interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1058-1062.	5.6	25
478	Chronic mucus hypersecretion in COPD and death from pulmonary infection. <i>European Respiratory Journal</i> , 1995, 8, 1333-1338.	6.7	220
479	Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. <i>European Respiratory Journal</i> , 1995, 8, 1694-1698.	6.7	93
480	Does Cytomegalovirus Predict a Poor Prognosis in <i>Pneumocystis carinii</i> Pneumonia Treated With Corticosteroids?. <i>Chest</i> , 1995, 108, 411-414.	0.8	48
481	Are Respiratory Symptoms and Chronic Airflow Limitation Really Associated with an Increased Risk of Respiratory Cancer?. <i>International Journal of Epidemiology</i> , 1991, 20, 375-378.	1.9	15
482	The Single-Breath Nitrogen Test, Mortality, and Cancer. <i>The American Review of Respiratory Disease</i> , 1990, 142, 1022-1025.	2.9	6
483	Predictive value of the single-breath nitrogen test for hospitalization due to respiratory disease. <i>Lung</i> , 1990, 168, 93-101.	3.3	5
484	Small-airways dysfunction in never smoking asbestos exposed Danish plumbers. <i>International Archives of Occupational and Environmental Health</i> , 1990, 62, 209-212.	2.3	4
485	Long-term exposure to cement dust and later hospitalization due to respiratory disease. <i>International Archives of Occupational and Environmental Health</i> , 1990, 62, 217-220.	2.3	27
486	Scintigraphic demonstration of the thoracic duct following oral ingestion of ¹²³ I-heptadecanoic acid. <i>Gastrointestinal Radiology</i> , 1989, 14, 212-214.	0.4	5

#	ARTICLE	IF	CITATIONS
487	Should We Continue Using Questionnaires on Breathlessness in Epidemiologic Surveys?. The American Review of Respiratory Disease, 1988, 137, 1114-1118.	2.9	49
488	Biomarkers to guide antibiotic therapy for COPD exacerbations. The Cochrane Library, 0, , .	2.8	0
489	Re-assessing the importance of FEV ₁ decline. , 0, , 134-142.		1